IL18BP and metabolic dysfunction-associated steatohepatitis: Treatment with anti-IL-18 antibody corrects liver defects in Il18bp−/− mice and ameliorates inflammation and fibrosis in diet-induced MASH mice, suggesting a translational treatment opportunity.